STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma

Genome Medicine

Volumn 6, Issue 1, 2014, Pages

  Evers, Lisa ^a   Perez Mancera, Pedro A ^b   Lenkiewicz, Elizabeth ^a   Tang, Nanyun ^a   Aust, Daniela ^c   Knösel, Thomas ^d   Rümmele, Petra ^e   Holley, Tara ^a   Kassner, Michelle ^a   Aziz, Meraj ^a   Ramanathan, Ramesh K ^a,f   Von Hoff, Daniel D ^a,f   Yin, Holly ^a   Pilarsky, Christian ^c   Barrett, Michael T ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f Virginia G Piper Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; K RAS PROTEIN; OXALIPLATIN; SMALL INTERFERING RNA; STAG2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPSY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA CONTENT; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE INSERTION; GENE SILENCING; GENETICALLY ENGINEERED MOUSE STRAIN; GENOME; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; TISSUE MICROARRAY; TRANSPOSON; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84896702480     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm526     Document Type: Article

References (30)

1. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. 10.1038/nature11547, 3530898, 23103869.
2. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806. 10.1126/science.1164368, 2848990, 18772397.
3. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011, 333:1039-1043. 10.1126/science.1203619, 3374335, 21852505.
4. Kolodner RD, Cleveland DW, Putnam CD. Cancer. Aneuploidy drives a mutator phenotype in cancer. Science 2011, 333:942-943. 10.1126/science.1211154, 3806716, 21852477.
5. Olesen SH, Thykjaer T, Orntoft TF. Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. Carcinogenesis 2001, 22:813-815. 10.1093/carcin/22.5.813, 11323402.
6. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649. 10.1038/25292, 9872311.
7. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303. 10.1038/32688, 9521327.
8. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Kufer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013, 45:1428-1430. 10.1038/ng.2800, 24121789.
9. Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grutzmann R, Aust D, Rummele P, Knosel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM, Wessels LF, et al. Australian Pancreatic Cancer Genome Initiative The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012, 486:266-270. 3376394, 22699621, Australian Pancreatic Cancer Genome Initiative.
10. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yeo CJ, Kern SE. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994, 54:2761-2764.
11. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473. 10.1038/ng1768, 16565718.
12. Rabinovitch PS, Dziadon S, Brentnall TA, Emond MJ, Crispin DA, Haggitt RC, Bronner MP. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 1999, 59:5148-5153.
13. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A 2011, 108:12054-12059. 10.1073/pnas.1104009108, 3141975, 21730190.
14. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. World Med J 2013, 59:199-202.
15. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007, 4:e67. 10.1371/journal.pmed.0040067, 1808095, 17326708.
16. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001, 96:3071-3083. 10.1111/j.1572-0241.2001.05261.x, 1559994, 11721752.
17. Von Hoff D, Ramanathan R, Evans D, Demeure MJ, Maney T, Wright B, Gatalica Z, McGinniss MJ, Piper VG. Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA), fluorescent in situ hybridization (FISH) and mutational analysis. J Clin Oncol 2012, 30:Abstract 4013.
18. The International Cell Line Authentication Committee (ICLAC). [http://standards.atcc.org/kwspub/home/the_international_cell_line_authentication_committee-iclac_/].
19. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117. 10.1038/nature09515, 3148940, 20981102.
20. Consortium EP, Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, Khatun J, Lajoie BR, Landt SG, Lee BK, Pauli F, Rosenbloom KR, Sabo P, Safi A, Sanyal A, Shoresh N, Simon JM, Song L, Trinklein ND, Altshuler RC, Birney E, Brown JB, Cheng C, Djebali S, Dong X, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. 10.1038/nature11247, 3439153, 22955616.
21. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010, 42:77-82. 10.1038/ng.491, 19946270.
22. Cox C, Bignell G, Greenman C, Stabenau A, Warren W, Stephens P, Davies H, Watt S, Teague J, Edkins S, Birney E, Easton DF, Wooster R, Futreal PA, Stratton MR. A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci U S A 2005, 102:4542-4547. 10.1073/pnas.0408593102, 555487, 15761058.
23. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607. 10.1038/nature11003, 3320027, 22460905.
24. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366:1090-1098. 10.1056/NEJMoa1106968, 3320218, 22417201.
25. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113. 10.1038/nature09460, 3137369,3137369, 20981101.
26. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44:694-698. 10.1038/ng.2256, 3819251, 22561517.
27. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, et al. The life history of 21 breast cancers. Cell 2012, 149:994-1007. 10.1016/j.cell.2012.04.023, 3428864,3428864, 22608083.
28. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. 3428862, 22722201.
29. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315:642-645. 10.1126/science.1137509, 17204608.
30. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat Rev Cancer 2004, 4:617-629. 10.1038/nrc1413, 15286741.